PANORAMIC: important insights into molnupiravir use in COVID-19

Michael R. Kidd; Paul M. Kelly

doi:10.1016/S0140-6736(22)02593-4

PANORAMIC: important insights into molnupiravir use in COVID-19

Michael R. Kidd, Paul M. Kelly

Research output: Contribution to journal › Comment/debate

10 Citations (Scopus)

Abstract

Oral antivirals have been an important addition to efforts to minimise adverse COVID-19 outcomes in individuals at high risk. Although no head-to-head comparisons of the widely available treatments molnupiravir and nirmatrelvir–ritonavir have been published, early trial findings (done largely in unvaccinated populations during pre-omicron SARS-CoV-2 waves) suggested less benefit from molnupiravir.

Original language	English
Pages (from-to)	250-251
Number of pages	2
Journal	The Lancet
Volume	401
Issue number	10373
DOIs	https://doi.org/10.1016/S0140-6736(22)02593-4
Publication status	Published - 28 Jan 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
molnupiravir
oral antivirals

Access to Document

10.1016/S0140-6736(22)02593-4Licence: In Copyright

Cite this

@article{c8fa0736375d4589a3a1a956ef662896,

title = "PANORAMIC: important insights into molnupiravir use in COVID-19",

abstract = "Oral antivirals have been an important addition to efforts to minimise adverse COVID-19 outcomes in individuals at high risk. Although no head-to-head comparisons of the widely available treatments molnupiravir and nirmatrelvir–ritonavir have been published, early trial findings (done largely in unvaccinated populations during pre-omicron SARS-CoV-2 waves) suggested less benefit from molnupiravir.",

keywords = "COVID-19, molnupiravir, oral antivirals",

author = "Kidd, {Michael R.} and Kelly, {Paul M.}",

year = "2023",

month = jan,

day = "28",

doi = "10.1016/S0140-6736(22)02593-4",

language = "English",

volume = "401",

pages = "250--251",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10373",

}

TY - JOUR

T1 - PANORAMIC

T2 - important insights into molnupiravir use in COVID-19

AU - Kidd, Michael R.

AU - Kelly, Paul M.

PY - 2023/1/28

Y1 - 2023/1/28

N2 - Oral antivirals have been an important addition to efforts to minimise adverse COVID-19 outcomes in individuals at high risk. Although no head-to-head comparisons of the widely available treatments molnupiravir and nirmatrelvir–ritonavir have been published, early trial findings (done largely in unvaccinated populations during pre-omicron SARS-CoV-2 waves) suggested less benefit from molnupiravir.

AB - Oral antivirals have been an important addition to efforts to minimise adverse COVID-19 outcomes in individuals at high risk. Although no head-to-head comparisons of the widely available treatments molnupiravir and nirmatrelvir–ritonavir have been published, early trial findings (done largely in unvaccinated populations during pre-omicron SARS-CoV-2 waves) suggested less benefit from molnupiravir.

KW - COVID-19

KW - molnupiravir

KW - oral antivirals

UR - http://www.scopus.com/inward/record.url?scp=85147093894&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)02593-4

DO - 10.1016/S0140-6736(22)02593-4

M3 - Comment/debate

C2 - 36566762

AN - SCOPUS:85147093894

SN - 0140-6736

VL - 401

SP - 250

EP - 251

JO - The Lancet

JF - The Lancet

IS - 10373

ER -

PANORAMIC: important insights into molnupiravir use in COVID-19

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this